Atopic Dermatitis Pipeline Outlook Report 2025: Insight into emerging drugs, treatment options, clinical trials, and company strategies

The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...
InvestorsHub on MSN

Arcutis Biotherapeutics Shares Rise After FDA Approves Eczema Cream for Young Children

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) shares gained 1.5% in premarket trading Monday after the U.S. Food and Drug ...
Managed Healthcare Executive

FDA Approves Zoryve Cream 0.05% for Young Children with Atopic Dermatitis

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...
Medscape

FDA Extends Topical Roflumilast’s Atopic Dermatitis Approval to Young Children

This approval follows the recent FDA approval of ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor, as a treatment ...
Morningstar

Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial

Sanofi said its amlitelimab experimental drug met all main goals in a late-stage clinical trial with eczema patients. The French pharmaceutical company said Thursday that amlitelimab showed efficacy ...

Lilly's Ebglyss® for moderate-to-severe atopic dermatitis (eczema) listed on Quebec's public drug formulary

Ebglyss® (lebrikizumab) to treat moderate-to-severe atopic dermatitis1 (eczema) has officially been listed on Québec's public ...
The Purdue Exponent

FDA Approves Opzelura for Atopic Dermatitis in Children

The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years ...

Atopic Dermatitis Pipeline Drugs Report 2025 by DelveInsight Highlighting Current Clinical Trials, Emerging Drug Classes, and Market Opportunities

DelveInsight’s “Atopic Dermatitis Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 120+ ...